National and Kapodistrian University of Athens
Μελέτη των πολυμορφισμών του κυτοχρώματος P450 και η επίδραση τους στη θεραπεία με αντιβιταμίνες K σε έλληνες ασθενείς
Abstract
dc:descriptionAcenocoumarol is mainly catabolized by CYP2C9 isoform of cytochrome P450 (CYP) liver complex and exerts its anticoagulant effect through the inhibition of Vitamin K Epoxide Reductase (VKOR). The most important genetic polymorphisms which lead to an impaired enzymatic activity and therefore predispose to acenocoumarol sensitivity, are considered to be CYP2C9*2 (Arg144Cys), CYP2C9*3 (Ile359Leu) and VKORC1-1639G[A, respectively. The aim of this study was to identify the association of CYP2C9*2(Arg144Cys), CYP2C9*3(Ile359Leu) and VKORC1 -1639G>A polymorphisms with acenocoumarol mean maintenance dose in Greek patients and to compare the results of the PGX-Thrombo StripAssay kit (ViennaLab Diagnostics,Vienna, Austria) with direct DNA sequencing and in house Restriction Fragment Length Polymorphisms (RFLP) for the detection of the aforementioned Single Nucleotide Polymorphisms (SNPs). A retrospective cohort study was conducted to 98 patients who met the inclusion criteria and gave an informed consent. The CYP2C9*2 and VKORC1 -1639G>A allelic variants were analyzed by PCR-RFLP(Polymerase chain rection followed by restriction endonuclease digestion), while CYP2C9*3 was genotyped by direct sequencing of PCR products. The aformentioned polymorphisms were also analysed performing the PGX-Thrombo StripAssay kit (ViennaLab Diagnostics,Vienna, Austria) in 40 of the 98 patients. Allelic frequencies of CYP2C9*2, CYP2C9*3 and VKORC1A were found to be 0.155, 0.075 and 0.485, respectively. Carriership of at least one CYP2C9*3 allele led to the most pronounced reduction in the required mean dose (p < 0.0001). In contrast, the CYP2C9*2 allele played a minor role (p = 0.3). VKORC1 A/A patients needed approximately a third of the dose required by wild-type patients to achieve the target INR (p < 0.0001). Age was the only demographical factor significantly affecting acenocoumarol dose (p < 0.0001). In a multivariable regression model, CYP2C9, VKORC1 genotypes and age explained 55% of acenocoumarol dosing variability. Furthermore, the reverse hybridization StripAssay kit was found to be equally effective with RFLP and direct DNA sequencing for the detection of CYP2C9*2 and CYP2C9*3 polymorphisms, respectively. The comparison of the RFLP reference method with the reverse hybridization StripAssay for the detection of VKORC1-1639 G[A polymorphism showed that the reverse hybridization StripAsssay might misclassify some A/A homozygotes as heterozygotes...
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Markatos, Christos
- Μαρκάτος, Χρήστος
Subjects
dc:subject × 20- Αντιβιταμίνες Κ
- Ασενοκουμαρόλη
- Ασενοκουμαρόλη, Ευαισθησία στην
- Ασενοκουμαρόλη, Αντίσταση στην
- Ασενοκουμαρόλη, Δοσολογικός αλγόριθμος
- Ασενοκουμαρόλη, Φαρμακογενετική
- Γενετικοί πολυμορφισμοί
- Κυτόχρωμα P450
- Antivitamins K
- Acenocoymarol
- Acenocoymarol sensitivity
- Acenocoymarol resistance
- Acenocoymarol dosage algorithm
- Acenocoymarol pharmacogenetics
- Cytochrome P450
- Genetic polymorphisms
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/23984